Platelet-derived growth factor-receptor α strongly inhibits melanoma growth in Vitro and in Vivo

Neoplasia

Volumn 11, Issue 8, 2009, Pages 732-742

  Faraone, Debora ^a   Aguzzi, Maria Simona ^b   Toietta, Gabriele ^b   Facchiano, Angelo M ^c   Facchiano, Francesco ^d   Magenta, Alessandra ^b   Martelli, Fabio ^b   Truffa, Silvia ^b   Cesareo, Eleonora ^b   Ribatti, Domenico ^e   Capogrossi, Maurizio C ^b   Facchiano, Antonio ^b  

^a CENTRO CARDIOLOGICO MONZINO   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c CNR   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; PHOSPHOPROTEIN PHOSPHATASE 2A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN C JUN; REGULATOR PROTEIN; SIGNAL REGULATORY PROTEIN ALPHA1; STAUROSPORINE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN MICROARRAY;

EID: 67650500874     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09408     Document Type: Article

References (53)

1. Heldin CH and Westermark B (1999). Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79, 1283-1316.
2. Andrae J, Gallini R, and Betsholtz C (2008). Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22, 1276-1312.
3. Hoch RV and Soriano P (2003). Roles of PDGF in animal development. Development 130, 4769-4784.
4. Rosenkranz S and Kazlauskas A (1999). Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors 16, 201-216.
5. Klinghoffer RA, Mueting-Nelsen PF, Faerman A, Shani M, and Soriano P (2001). The two PDGF receptors maintain conserved signaling in vivo despite divergent embryological functions. Mol Cell 7, 343-354.
6. Heldin CH, Ostman A, and Ronnstrand L (1998). Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1378, F79-F113.
7. Koyama N, Hart CE, and Clowes AW (1994). Different functions of the platelet-derived growth factor-alpha and -beta receptors for the migration and proliferation of cultured baboon smooth muscle cells. Circ Res 75, 682-691.
8. Clunn GF, Refson JS, Lymn JS, and Hughes AD (1997). Platelet-derived growth factor beta-receptors can both promote and inhibit chemotaxis in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17, 2622-2629.
9. Facchiano A, De Marchis F, Turchetti E, Facchiano F, Guglielmi M, Denaro A, Palumbo R, Scoccianti M, and Capogrossi MC (2000). The chemotactic and mitogenic effects of platelet-derived growth factor-BB on rat aorta smooth muscle cells are inhibited by basic fibroblast growth factor. J Cell Sci 113, 2855-2863.
10. De Marchis F, Ribatti D, Giampietri C, Lentini A, Faraone D, Scoccianti M, Capogrossi MC, and Facchiano A (2002). Platelet-derived growth factor inhibits basic fibroblast growth factor angiogenic properties in vitro and in vivo through its alpha receptor. Blood 99, 2045-2053.
11. Yu J, Liu XW, and Kim HR (2003). Platelet-derived growth factor (PDGF) receptor-alpha-activated c-Jun NH2-terminal kinase-1 is critical for PDGFinduced p21WAF1/CIP1 promoter activity independent of p53. J Biol Chem 278, 49582-49588.
12. Faraone D, Aguzzi MS, Ragone G, Russo K, Capogrossi MC, and Facchiano A (2006). Heterodimerization of FGF-receptor 1 and PDGF-receptor-alpha: a novel mechanism underlying the inhibitory effect of PDGF-BB on FGF-2 in human cells. Blood 107, 1896-1902.
13. Hocker TL, Singh MK, and Tsao H (2008). Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol 128, 2575-2595.
14. Shen SS, Zhang PS, Eton O, and Prieto VG (2003). Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol 30, 539-547.
15. Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, and Sosman JA (2006). Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106, 2005-2011.
16. Palumbo R, Gaetano C, Antonini A, Pompilio G, Bracco E, Ronnstrand L, Heldin CH, and Capogrossi MC (2002). Different effects of high and low shear stress on platelet-derived growth factor isoform release by endothelial cells: consequences for smooth muscle cell migration. Arterioscler Thromb Vasc Biol 22, 405-411.
17. Gorospe M, Cirielli C, Wang X, Seth P, Capogrossi MC, and Holbrook NJ (1997). p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene 14, 929-935.
18. Lacal PM, Failla CM, Pagani E, Odorisio T, Schietroma C, Falcinelli S, Zambruno G, and D'Atri S (2000). Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 115, 1000-1007.
19. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, and Vogelstein B (1998). A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95, 2509-2514.
20. Cicchillitti L, Fasanaro P, Biglioli P, Capogrossi MC, and Martelli F (2003). Oxidative stress induces protein phosphatase 2A-dependent dephosphorylation of the pocket proteins pRb, p107, and p130. J Biol Chem 278, 19509-19517.
21. Magenta A, Fasanaro P, Romani S, Di Stefano V, Capogrossi MC, and Martelli F (2008). Protein phosphatase 2A subunit PR70 interacts with pRb and mediates its dephosphorylation. Mol Cell Biol 28, 873-882.
22. Quackenbush J (2002). Microarray data normalization and transformation. Nat Genet 32, 496-501.
23. Marcellini M, De Luca N, Riccioni T, Ciucci A, Orecchia A, Lacal PM, Ruffini F, Pesce M, Cianfarani F, Zambruno G, et al. (2006). Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor. Am J Pathol 169, 643-654.
24. McGary EC, Onn A, Mills L, Heimberger A, Eton O, Thomas GW, Shtivelband M, and Bar-Eli M (2004). Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J Invest Dermatol 122, 400-405.
25. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, Atkins D, and Wang Y (2005). Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 11, 7234-7242.
26. Smith AP, Hoek K, and Becker D (2005). Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther 4, 1018-1029 (E-pub 2005 Sep 1019).
27. Nindl I, Dang C, Forschner T, Kuban RJ, Meyer T, Sterry W, and Stockfleth E (2006). Identification of differentially expressed genes in cutaneous squamous cell carcinoma by microarray expression profiling. Mol Cancer 5, 30.
28. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E, Trombetta ES, et al. (2004). Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 64, 5270-5282.
29. Grosios K (2001). UCN-01 Kyowa Hakko Kogyo Co. Curr Opin Investig Drugs 2, 287-297.
30. Millward MJ, House C, Bowtell D,Webster L, Olver IN, Gore M, Copeman M, Lynch K, Yap A, Wang Y, et al. (2006). The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study. Br J Cancer 95, 829-834.
31. Zhang XD, Gillespie SK, and Hersey P (2004). Staurosporine induces apoptosis of melanoma by both caspase-dependent and -independent apoptotic pathways. Mol Cancer Ther 3, 187-197.
32. Lindroos PM, Wang YZ, Rice AB, and Bonner JC (2001). Regulation of PDGFR-alpha in rat pulmonary myofibroblasts by staurosporine. Am J Physiol Lung Cell Mol Physiol 280, L354-L362.
33. Knudsen KE, Booth D, Naderi S, Sever-Chroneos Z, Fribourg AF, Hunton IC, Feramisco JR, Wang JY, and Knudsen ES (2000). RB-dependent S-phase response to DNA damage. Mol Cell Biol 20, 7751-7763.
34. Cobrinik D(2005). Pocket proteins and cell cycle control. Oncogene 24, 2796-2809.
35. Lewis TB, Robison JE, Bastien R, Milash B, Boucher K, Samlowski WE, Leachman SA, Dirk Noyes R, Wittwer CT, Perreard L, et al. (2005). Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction. Cancer 104, 1678-1686.
36. Metheny-Barlow LJ, Flynn B, van Gijssel HE, Marrogi A, and Gerwin BI (2001). Paradoxical effects of platelet-derived growth factor-A overexpression in malignant mesothelioma. Antiproliferative effects in vitro and tumorigenic stimulation in vivo. Am J Respir Cell Mol Biol 24, 694-702.
37. Kim HR, Upadhyay S, Li G, Palmer KC, and Deuel TF (1995). Platelet-derived growth factor induces apoptosis in growth-arrested murine fibroblasts. Proc Natl Acad Sci USA 92, 9500-9504.
38. Beck KF, Guder G, Schaefer L, Pleskova M, Babelova A, Behrens MH, Mihalik D, Beck M, Schaefer RM, and Pfeilschifter J (2005). Nitric oxide upregulates induction of PDGF receptor-alpha expression in rat renal mesangial cells and in anti-Thy-1 glomerulonephritis. J Am Soc Nephrol 16, 1948-1957.
39. Wang C, Wang MW, Tashiro S, Onodera S, and Ikejima T (2005). IL-1beta acts in synergy with endogenous IL-1beta in A375-S2 human melanoma cell apoptosis through mitochondrial pathway. J Korean Med Sci 20, 555-561.
40. Lih CJ, Cohen SN, Wang C, and Lin-Chao S (1996). The platelet-derived growth factor alpha-receptor is encoded by a growth-arrest-specific ( gas) gene. Proc Natl Acad Sci USA 93, 4617-4622.
41. VanBrocklin MW, Verhaegen M, Soengas MS, and Holmen SL (2009). Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. Cancer Res 69, 1985-1994.
42. Eskandarpour M, Kiaii S, Zhu C, Castro J, Sakko AJ, and Hansson J (2005). Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int J Cancer 115, 65-73.
43. Wang YF, Jiang CC, Kiejda KA, Gillespie S, Zhang XD, and Hersey P (2007). Apoptosis induction in human melanoma cells by inhibition of MEK is caspaseindependent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res 13, 4934-4942.
44. Bedikian AY, Plager C, Stewart JR, O'Brian CA, Herdman SK, Ross M, Papadopoulos N, Eton O, Ellerhorst J, and Smith T (2001). Phase II evaluation of bryostatin-1 in metastatic melanoma. Melanoma Res 11, 183-188.
45. Edelman MJ, Bauer KS Jr, Wu S, Smith R, Bisacia S, and Dancey J (2007). Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. Clin Cancer Res 13, 2667-2674.
46. Maksimovic-Ivanic D, Mijatovic S, Harhaji L, Miljkovic D, Dabideen D, Fan Cheng K, Mangano K, Malaponte G, Al-Abed Y, Libra M, et al. (2008). Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4, 5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo. Mol Cancer Ther 7, 510-520.
47. Pillaire MJ, Nebreda AR, and Darbon JM (2000). Cisplatin and UV radiation induce activation of the stress-activated protein kinase p38gamma in human melanoma cells. Biochem Biophys Res Commun 278, 724-728.
48. Wang X, McGowan CH, Zhao M, He L, Downey JS, Fearns C, Wang Y, Huang S, and Han J (2000). Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced cell cycle arrest. Mol Cell Biol 20, 4543-4552.
49. Cant CA and Ullrich A (2001). Signal regulation by family conspiracy. Cell Mol Life Sci 58, 117-124.
50. Yamasaki Y, Ito S, Tsunoda N, Kokuryo T, Hara K, Senga T, Kannagi R, Yamamoto T, Oda K, Nagino M, et al. (2007). SIRPalpha1 and SIRPalpha2: their role as tumor suppressors in breast carcinoma cells. Biochem Biophys Res Commun 361, 7-13.
51. Zhang G, Dass CR, Sumithran E, Di Girolamo N, Sun LQ, and Khachigian LM (2004). Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst 96, 683-696.
52. Ugurel S, Hildenbrand R, Zimpfer A, La Rosee P, Paschka P, Sucker A, Keikavoussi P, Becker JC, Rittgen W, Hochhaus A, et al. (2005). Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92, 1398-1405.
53. Anderberg C, Li H, Fredriksson L, Andrae J, Betsholtz C, Li X, Eriksson U, and Pietras K (2009). Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res 69, 369-378.